Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Trimethobenzamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.96 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.96 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | DRD3 | P35462 | 2/20 | 0.96 |
| ▸ | LMNA | P02545 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.94 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.94 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.77 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethobenzamide SCHEMBL6683399 | 0.98 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL28858 | 0.98 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586062 | 0.97 | DRD2 (0.98) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586216 | 0.97 | SMN1; SMN2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL41339 | 0.97 | SMN1; SMN2 (1.00) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586290 | 0.97 | DRD2 (0.98) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586023 | 0.95 | DRD2 (0.94) | DRD2DRD3LMNAACHESLC6A2 | |
| Trimethobenzamide SCHEMBL4586233 | 0.94 | DRD2 (0.92) | DRD2DRD3LMNAACHESLC6A2 | |
| Itopride SCHEMBL1650211 | 0.89 | DRD2 (0.96) | DRD2DRD3LMNAACHESLC6A2 | |
| Itopride SCHEMBL311309 | 0.87 | DRD2 (1.00) | DRD2DRD3LMNAACHESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250259704-A1 | SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS | U.S. DEPARTMENT OF ENERGY | 2025-08-14 | — | — | US | disclosed |
| CN-101896161-A | Solid formulations of crystalline compounds | PURDUE RESEARCH FOUNDATION | 2010-11-24 | — | — | CN | disclosed |
| US-20100222311-A1 | SOLID FORMULATIONS OF CRYSTALLINE COMPOUNDS | PURDUE RESEARCH FOUNDATION (US) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ACHE 281/4885SLC6A2 804/4885DRD2 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.